anisodamine has been researched along with Cirrhosis, Liver in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Luo, L; Zhou, A | 1 |
| Dai, M; Guo, K; Li, Y; Shen, W; Yang, H | 1 |
1 trial(s) available for anisodamine and Cirrhosis, Liver
| Article | Year |
|---|---|
[Clinical observation of the treatment of 654-2 injection and "ganxian tui huang recipe" on liver cirrhosis with intractable jaundice].
Topics: Adult; Aged; Drug Combinations; Drug Synergism; Drugs, Chinese Herbal; Female; Follow-Up Studies; Humans; Jaundice; Liver Cirrhosis; Male; Middle Aged; Phytotherapy; Plants, Medicinal; Solanaceous Alkaloids | 2003 |
1 other study(ies) available for anisodamine and Cirrhosis, Liver
| Article | Year |
|---|---|
Antifibrotic activity of anisodamine in vivo is associated with changed intrahepatic levels of matrix metalloproteinase-2 and its inhibitor tissue inhibitors of metalloproteinases-2 and transforming growth factor beta1 in rats with carbon tetrachloride-in
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Carbon Tetrachloride; Extracellular Matrix; Hyaluronic Acid; Immunohistochemistry; Liver Cirrhosis; Malondialdehyde; Matrix Metalloproteinase 2; Random Allocation; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Solanaceous Alkaloids; Staining and Labeling; Tissue Inhibitor of Metalloproteinase-2; Transforming Growth Factor beta1 | 2009 |